Page last updated: 2024-12-05

homoarginine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Homoarginine (HArg) is a naturally occurring amino acid that is structurally similar to arginine. It is synthesized in the body through the methylation of arginine by the enzyme arginine N-methyltransferase (PRMT1). HArg has been shown to have a variety of biological effects, including vasodilation, anti-inflammatory effects, and protective effects against cardiovascular disease. It is also a substrate for nitric oxide synthase (NOS), an enzyme that produces nitric oxide (NO), a key signaling molecule involved in vasodilation and other physiological processes. HArg has been studied as a potential therapeutic agent for a variety of conditions, including hypertension, heart failure, and diabetes. Its importance in research stems from its potential as a therapeutic target and its role in maintaining cardiovascular health. The study of HArg focuses on understanding its mechanisms of action, its role in various physiological processes, and its potential as a therapeutic agent.'

L-homoarginine : An L-lysine derivative that is the L-enantiomer of homoarginine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9085
CHEMBL ID589752
CHEBI ID27747
SCHEMBL ID43287
SCHEMBL ID21802133
MeSH IDM0010513

Synonyms (56)

Synonym
nsc-88868
nsc-27429
l-lysine, n6-(aminoiminomethyl)-
l-n(sup 6)-amidinolysine
nsc 27429
lysine, n(sup 6)-amidino-, l-
l-lysine, n(sup 6)-(aminoiminomethyl)-
C01924
homoarginine ,
l-homoarginine
156-86-5
HRG ,
n6-amidino-l-lysine
n6-(aminoiminomethyl)-l-lysine
n6-amidino-lysine
DB03974
homo-l-arginine
(2s)-2-amino-6-(diaminomethylideneamino)hexanoic acid
CHEMBL589752 ,
chebi:27747 ,
l-lysine, n6-(aminoiminomethyl)- (9ci)
BMSE000745
bdbm50309588
A809778
AKOS006282043
h-homoarg-oh
l-lysine, n(6)-(aminoiminomethyl)-
unii-jf751ck38i
jf751ck38i ,
l-n(6)-amidinolysine
h-hoarg-oh
AKOS015894481
S6109
SCHEMBL43287
(s)-2-amino-6-guanidinohexanoic acid
Q-201303
n6-carbamimidoyl-l-lysine
lysine, n6-amidino-, l-
13094-78-5
lysine, n6-amidino-
homoarginine, l-
(2s)-2-amino-6-carbamimidamidohexanoic acid
CS-W008385
(s)-2-amino-6-guanidinohexanoic acid (h-l-harg-oh)
mfcd00237108
h-homoarginine
HY-W008385
n~6~-carbamimidoyl-l-lysine
n~6~-carbamimidoyllysine
DTXSID70926980
Q57828472
SCHEMBL21802133
DS-15039
AMY22584
AC2507
l-homoarg-oh

Research Excerpts

Overview

Homoarginine is a non-essential cationic amino acid which inhibits hepatic alkaline phosphatases to exert inhibitory effects on bile secretion by targeting intrahepatic biliary epithelium. Homoarg inine is an amino acid that may be involved in nitric oxide and energy metabolism.

ExcerptReferenceRelevance
"Homoarginine is an endogenous amino acid whose levels are reduced in patients with renal, cardio- and cerebrovascular disease. "( Population kinetics of homoarginine and optimized supplementation for cardiovascular risk reduction.
Atzler, D; Böger, R; Choe, CU; Kleist, CJ; Schönhoff, M; Schwedhelm, E; Wicha, SG, 2022
)
2.47
"Homoarginine (hArg) is an endogenous, nonproteinogenic amino acid. "( Homoarginine in health and disease.
Tsikas, D, 2023
)
3.8
"Homoarginine (hArg) is a non-essential cationic amino acid which inhibits hepatic alkaline phosphatases to exert inhibitory effects on bile secretion by targeting intrahepatic biliary epithelium. "( The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies.
Aghdassi, A; Atzler, D; Bahls, M; Dörr, M; Felix, SB; Ittermann, T; Kromrey, ML; Kühn, JP; Nauck, M; Schwedhelm, E; Völzke, H, 2023
)
2.66
"l-homoarginine (l-hArg) is an endogenous non-proteinogenic amino acid. "( Cognitive performance of 20 healthy humans supplemented with L-homoarginine for 4 weeks.
Atzler, D; Böger, R; Choe, CU; Cordts, K; Gerloff, C; Hoppe, J; Hornig, S; Neu, A; Schönhoff, M; Schwedhelm, E; Weineck, G, 2018
)
1.44
"Homoarginine is an amino acid derivative mainly synthesized in the kidney. "( Homoarginine and progression of chronic kidney disease: results from the Mild to Moderate Kidney Disease Study.
Drechsler, C; Kollerits, B; König, P; Kronenberg, F; März, W; Meinitzer, A; Neyer, U; Pilz, S; Ritz, E; Wanner, C, 2013
)
3.28
"Homoarginine is an amino acid that may be involved in nitric oxide and energy metabolism. "( Homoarginine and mortality in an older population: the Hoorn study.
Dekker, JM; Drechsler, C; Kienreich, K; März, W; Meinitzer, A; Nijpels, G; Pilz, S; Rutters, F; Scheffer, PG; Stehouwer, CD; Teerlink, T; Tomaschitz, A, 2014
)
3.29
"Homoarginine is a novel biomarker for cardiovascular diseases. "( Homoarginine, kidney function and cardiovascular mortality risk.
Boehm, BO; Drechsler, C; Fahrleitner-Pammer, A; Genser, B; Grammer, T; Kleber, ME; Kraigher-Krainer, E; Krane, V; März, W; Meinitzer, A; Pieske, B; Pilz, S; Ritz, E; Rus-Machan, J; Tomaschitz, A; Wanner, C, 2014
)
3.29
"L-Homoarginine is a cationic amino acid derivative, which is structurally related to L-arginine and lysine. "( Possible sources and functions of L-homoarginine in the brain: review of the literature and own findings.
Bernstein, HG; Bogerts, B; Dobrowolny, H; Jäger, K; Keilhoff, G; Laube, G; Steiner, J, 2015
)
1.41
"Homoarginine (hArg) is an endogenous, nonproteinogenic amino acid which differs from arginine by an additional methylene (CH2) group in the backbone. "( Homoarginine in the renal and cardiovascular systems.
Alesutan, I; Drechsler, C; Gaksch, M; Grübler, M; Hartaigh, BÓ; Lang, F; März, W; Meinitzer, A; Pilz, S; Tomaschitz, A; Verheyen, N; Voelkl, J, 2015
)
3.3
"L-Homoarginine (hArg) is an endogenous amino acid which has emerged as a novel biomarker for stroke and cardiovascular disease. "( Homoarginine supplementation improves blood glucose in diet-induced obese mice.
Atzler, D; Böger, RH; Choe, CU; Cordts, K; Hornig, S; Isbrandt, D; Neu, A; Schwedhelm, E; Stockebrand, M, 2015
)
2.58
"Homoarginine (hArg) is a non-essential amino acid that was identified as a risk marker for cardiovascular disease. "( Measurement of homoarginine in human and mouse plasma by LC-MS/MS and ELISA: a comparison and a biological application.
Atzler, D; Böger, RH; Choe, CU; Cordts, K; Qaderi, V; Schwedhelm, E; Sydow, K, 2015
)
2.21
"Homoarginine is an amino acid derivative that may increase nitric oxide availability and enhance endothelial function. "( Homoarginine, cardiovascular risk, and mortality.
Böhm, BO; Drechsler, C; Fischer, J; Kleber, ME; Krane, V; März, W; Meinitzer, A; Pilz, S; Ritz, E; Wanner, C; Winkelmann, BR, 2010
)
3.25
"Low homoarginine levels are a novel risk factor for fatal strokes and are reduced in patients with a history of cerebrovascular disease. "( Low serum homoarginine is a novel risk factor for fatal strokes in patients undergoing coronary angiography.
Böhm, BO; Drechsler, C; Krane, V; März, W; Meinitzer, A; Pilz, S; Ritz, E; Tomaschitz, A; Wanner, C, 2011
)
1.33
"Homoarginine is an amino acid which may play a role in nitric oxide and energy metabolism. "( Low homoarginine concentration is a novel risk factor for heart disease.
Boehm, BO; Drechsler, C; Krane, V; März, W; Meinitzer, A; Pilz, S; Ritz, E; Tomaschitz, A; Wanner, C, 2011
)
2.37
"Low homoarginine is a strong risk factor for SCD and death due to heart failure in haemodialysis patients. "( Homoarginine, heart failure, and sudden cardiac death in haemodialysis patients.
Drechsler, C; Krane, V; März, W; Meinitzer, A; Pilz, S; Ritz, E; Tomaschitz, A; Wanner, C, 2011
)
2.37

Effects

L-Homoarginine (hArg) has recently emerged as a novel cardiovascular risk factor and to herald a poor prognosis in heart failure patients. The homoarginne technique has been suggested as a means to determine true ileal amino acid digestibilities.

ExcerptReferenceRelevance
"Homoarginine (hArg) has been shown to be of prognostic value in patients with chronic left heart failure. "( Homoarginine-A prognostic indicator in adolescents and adults with complex congenital heart disease?
Dschietzig, T; Maerz, W; Meinitzer, A; Mueller, M; Raedle-Hurst, T, 2017
)
3.34
"L-Homoarginine (hArg) has recently emerged as a novel cardiovascular risk factor and to herald a poor prognosis in heart failure patients. "( GC-MS and GC-MS/MS measurement of the cardiovascular risk factor homoarginine in biological samples.
Beckmann, B; Gutzki, FM; Jordan, J; Kayacelebi, AA; Tsikas, D, 2014
)
1.36
"The homoarginine technique has been suggested as a means to determine true ileal amino acid digestibilities in nonruminant animals fed protein-containing diets. "( Evaluation of the homoarginine technique for measuring true ileal amino acid digestibilities in pigs fed a barley-canola meal-based diet.
de Lange, CF; Gabert, VM; McNeilage-Van de Wiele, EM; Nyachoti, CM, 2002
)
1.21

Treatment

ExcerptReferenceRelevance
"Homoarginine-treated mice exhibited reduced atherosclerosis in the aortic root and brachiocephalic trunk."( The Amino Acid Homoarginine Inhibits Atherogenesis by Modulating T-Cell Function.
Ammar, C; Atzler, D; Bianchini, M; Bonfiglio, CA; Burger, C; Duchene, J; Forné, I; Heemskerk, JWM; Huveneers, S; Imhof, A; Janjic, A; Kücükgöze, IA; Lacy, M; Li, Y; Lutgens, E; Lygate, CA; Megens, RTA; Migheli, R; Mohanta, S; Nitz, K; Santovito, D; Schwedhelm, E; Weber, C; Wichapong, K; Wu, Y; Zimmer, R, 2022
)
1.8

Compound-Compound Interactions

ExcerptReferenceRelevance
" Experiments were designed to assess the potential chemopreventive properties of highly selective iNOS inhibitors, administered individually and in combination with a selective COX-2 inhibitor, on the development of AOM-induced colonic aberrant crypt foci (ACF)."( Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Connor, JR; Indranie, C; Manning, PT; Rao, CV; Reddy, BS; Simi, B, 2002
)
0.31

Bioavailability

L-Arg and homoarginine are substrates of NO generating synthase. dimethylarginines (SDMA, ADMA) can interfere with bioavailability and function of the main NO-donor L-Arg.

ExcerptReferenceRelevance
" The low bioavailability obtained was mainly due to the high polarity of iothalamate molecules as suggested by the GI recovery and in vitro partition studies."( Absorption of iothalamate after oral administration and absorption enhancement by amino acids in dogs and rats.
Chiou, WL; Hsu, FH; Lee, MG; Prueksaritanont, T,
)
0.13
"Diabetes mellitus is associated with decreased nitric oxide bioavailability thereby affecting renal blood flow regulation."( Cellular transport of l-arginine determines renal medullary blood flow in control rats, but not in diabetic rats despite enhanced cellular uptake capacity.
Fasching, A; Hansell, P; Palm, F; Persson, P; Teerlink, T, 2017
)
0.46
" Surrogate markers for NO bioavailability are substrates of NO generating synthase (NOS): L-arginine (lArg) and homoarginine (hArg) together with the inhibitory competitive substrate asymmetric dimethylarginine (ADMA)."( Markers of nitric oxide are associated with sepsis severity: an observational study.
Bauer, A; Böger, RH; Goetz, AE; Holzmann, M; Kluge, S; Moritz, E; Nierhaus, A; Priefler, M; Robbe, L; Schwedhelm, E; Winkler, MS; Zahrte, C; Zoellner, C, 2017
)
0.67
" Both metabolites affect NO metabolism and our findings suggest reduced NO bioavailability in sepsis."( Markers of nitric oxide are associated with sepsis severity: an observational study.
Bauer, A; Böger, RH; Goetz, AE; Holzmann, M; Kluge, S; Moritz, E; Nierhaus, A; Priefler, M; Robbe, L; Schwedhelm, E; Winkler, MS; Zahrte, C; Zoellner, C, 2017
)
0.46
"Nitric oxide plays a major role in the regulation of blood pressure, and impaired nitric oxide bioavailability contributes to the development of hypertension (HT)."( Homoarginine and blood pressure: a 10-year prospective relationship in normotensives.
Böger, R; Botha-Le Roux, S; Fourie, CMT; Mels, CMC; Mokhaneli, MC; Schwedhelm, E, 2022
)
2.16
"Guanidino compounds such as dimethylarginines (SDMA, ADMA) and L-homoarginine ((L-)hArg) can interfere with bioavailability and function of the main NO-donor L-arginine (L-Arg)."( Developmental dynamics of homoarginine, ADMA and SDMA plasma levels from birth to adolescence.
Baach, F; Böger, R; Choe, CU; Lezius, S; Meyer, B; Neu, A; Oh, J; Schwedhelm, E, 2023
)
1.45

Dosage Studied

ExcerptRelevanceReference
" We developed a pharmacometric model to evaluate different dosing regimens, especially the regimen of 125 mg once weekly, based on a previous clinical study (n = 20)."( Population kinetics of homoarginine and optimized supplementation for cardiovascular risk reduction.
Atzler, D; Böger, R; Choe, CU; Kleist, CJ; Schönhoff, M; Schwedhelm, E; Wicha, SG, 2022
)
1.03
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
EC 3.1.3.1 (alkaline phosphatase) inhibitorAn EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of alkaline phosphatase (EC 3.1.3.1).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
xenobiotic metaboliteAny metabolite produced by metabolism of a xenobiotic compound.
rat metaboliteAny mammalian metabolite produced during a metabolic reaction in rat (Rattus norvegicus).
biomarkerA substance used as an indicator of a biological state.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
homoarginine
L-lysine derivativeA proteinogenic amino acid derivative resulting from reaction of L-lysine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-lysine by a heteroatom.
non-proteinogenic L-alpha-amino acidAny L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)IC50 (µMol)5.00000.01502.24078.6000AID459065
Phospholipase A-2-activating proteinHomo sapiens (human)IC50 (µMol)5.00000.01101.53702.5000AID459064
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (38)

Processvia Protein(s)Taxonomy
skeletal system developmentAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
osteoblast differentiationAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
endochondral ossificationAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
developmental process involved in reproductionAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
cellular homeostasisAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
bone mineralizationAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to lipopolysaccharideAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to insulinAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to vitamin DAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to vitamin B6Alkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to macrophage colony-stimulating factorAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
pyridoxal phosphate metabolic processAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to antibioticAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to glucocorticoidAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
phosphate ion homeostasisAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
calcium ion homeostasisAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
cellular response to organic cyclic compoundAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
cementum mineralizationAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
positive regulation of cold-induced thermogenesisAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
futile creatine cycleAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
inhibition of non-skeletal tissue mineralizationAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to sodium phosphateAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
dephosphorylationAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
dephosphorylationIntestinal-type alkaline phosphataseHomo sapiens (human)
phospholipid metabolic processPhospholipase A-2-activating proteinHomo sapiens (human)
prostaglandin metabolic processPhospholipase A-2-activating proteinHomo sapiens (human)
inflammatory responsePhospholipase A-2-activating proteinHomo sapiens (human)
signal transductionPhospholipase A-2-activating proteinHomo sapiens (human)
nervous system developmentPhospholipase A-2-activating proteinHomo sapiens (human)
macroautophagyPhospholipase A-2-activating proteinHomo sapiens (human)
positive regulation of phospholipase A2 activityPhospholipase A-2-activating proteinHomo sapiens (human)
ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathwayPhospholipase A-2-activating proteinHomo sapiens (human)
cellular response to lipopolysaccharidePhospholipase A-2-activating proteinHomo sapiens (human)
negative regulation of protein K63-linked ubiquitinationPhospholipase A-2-activating proteinHomo sapiens (human)
positive regulation of synaptic vesicle recyclingPhospholipase A-2-activating proteinHomo sapiens (human)
positive regulation of dendrite extensionPhospholipase A-2-activating proteinHomo sapiens (human)
positive regulation of neuron migrationPhospholipase A-2-activating proteinHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processPhospholipase A-2-activating proteinHomo sapiens (human)
ubiquitin recyclingPhospholipase A-2-activating proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
alkaline phosphatase activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
inorganic diphosphate phosphatase activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
calcium ion bindingAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
pyrophosphatase activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
ATP hydrolysis activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
pyridoxal phosphatase activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
ADP phosphatase activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
phosphoamidase activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
phosphoethanolamine phosphatase activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
magnesium ion bindingIntestinal-type alkaline phosphataseHomo sapiens (human)
protease bindingIntestinal-type alkaline phosphataseHomo sapiens (human)
alkaline phosphatase activityIntestinal-type alkaline phosphataseHomo sapiens (human)
protein bindingIntestinal-type alkaline phosphataseHomo sapiens (human)
zinc ion bindingIntestinal-type alkaline phosphataseHomo sapiens (human)
protein bindingPhospholipase A-2-activating proteinHomo sapiens (human)
phospholipase A2 activator activityPhospholipase A-2-activating proteinHomo sapiens (human)
ubiquitin bindingPhospholipase A-2-activating proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
mitochondrial intermembrane spaceAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
plasma membraneAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
mitochondrial membraneAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
extracellular regionAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
plasma membraneAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
membraneAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
extracellular matrixAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
extracellular exosomeAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
side of membraneAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
extracellular regionIntestinal-type alkaline phosphataseHomo sapiens (human)
plasma membraneIntestinal-type alkaline phosphataseHomo sapiens (human)
side of membraneIntestinal-type alkaline phosphataseHomo sapiens (human)
plasma membraneIntestinal-type alkaline phosphataseHomo sapiens (human)
nucleusPhospholipase A-2-activating proteinHomo sapiens (human)
cytoplasmPhospholipase A-2-activating proteinHomo sapiens (human)
synapsePhospholipase A-2-activating proteinHomo sapiens (human)
extracellular exosomePhospholipase A-2-activating proteinHomo sapiens (human)
cytoplasmPhospholipase A-2-activating proteinHomo sapiens (human)
nucleusPhospholipase A-2-activating proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID513345Antibacterial activity against Bacillus subtilis 1A40 at 1 mM after 3 hrs by CLSI method2007Nature chemical biology, Jan, Volume: 3, Issue:1
Antibacterial lysine analogs that target lysine riboswitches.
AID459065Inhibition of TNAP by analogous luminescence assay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Design and synthesis of selective inhibitors of placental alkaline phosphatase.
AID1204889Binding affinity to lysC riboswitch in Bacillus subtilis2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
(Dis)similar Analogues of Riboswitch Metabolites as Antibacterial Lead Compounds.
AID513346Inhibition of wild-type Bacillus subtilis 168 1A1 lysine riboswitch 179 lysc assessed as reduction of beta-galactosidase activity at 5 mM after 3 hrs by lacZ reporter gene assay2007Nature chemical biology, Jan, Volume: 3, Issue:1
Antibacterial lysine analogs that target lysine riboswitches.
AID459066Inhibition of IAP by analogous luminescence assay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Design and synthesis of selective inhibitors of placental alkaline phosphatase.
AID513357Antibacterial activity against Bacillus subtilis 168 1A1 after 24 hrs by CLSI method2007Nature chemical biology, Jan, Volume: 3, Issue:1
Antibacterial lysine analogs that target lysine riboswitches.
AID513343Binding affinity to Bacillus subtilis 168 1A1 lysine riboswitch 179 lysc by in-line probing assay2007Nature chemical biology, Jan, Volume: 3, Issue:1
Antibacterial lysine analogs that target lysine riboswitches.
AID459064Inhibition of PLAP by analogous luminescence assay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Design and synthesis of selective inhibitors of placental alkaline phosphatase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (347)

TimeframeStudies, This Drug (%)All Drugs %
pre-199074 (21.33)18.7374
1990's49 (14.12)18.2507
2000's43 (12.39)29.6817
2010's127 (36.60)24.3611
2020's54 (15.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.15 (24.57)
Research Supply Index5.94 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index56.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials19 (5.26%)5.53%
Reviews18 (4.99%)6.00%
Case Studies3 (0.83%)4.05%
Observational7 (1.94%)0.25%
Other314 (86.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]